FDA
-
-
-
-
-
-
-
Cabaletta Bio Inc. (CABA) PT Lowered to $15 at Guggenheim
-
-
-
-
-
-
-
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
-
-
-
-
-
-
-
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
-
-
-
-
-
-
-
Cabaletta Bio (CABA) Granted FDA Orphan Drug Designation to CABA-201
-
-
-
-
-
-
-
Cabaletta Bio (CABA) Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
-
-
-
-
-
-
-
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

